PolyPid Announces Presentation at the 2022 Military Health System Research Symposium
PolyPid Ltd. (Nasdaq: PYPD) announced the presentation of Phase 2 clinical and animal study data for D-PLEX100 at the 2022 Military Health System Research Symposium from September 12-15, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) announced the presentation of Phase 2 clinical and animal study data for D-PLEX100 at the 2022 Military Health System Research Symposium from September 12-15, 2022. The podium presentation will address D-PLEX100's efficacy in reducing surgical site infection rates and drug-resistant bacteria in surgical trauma injuries. This presentation will be led by Noam Emanuel, PhD, Co-Founder and Chief Scientific Officer. D-PLEX100 is currently in Phase 3 trials aimed at preventing surgical site infections.
Positive
- D-PLEX100 shows promise in reducing surgical site infections and drug-resistant bacteria.
- Presentation at a reputable symposium could enhance visibility and credibility in the medical community.
- D-PLEX100 is in Phase 3 trials, indicating progress in development.
Negative
- No specific clinical trial results or data shared could lead to uncertainty regarding effectiveness.
- Dependency on successful trial outcomes for future market viability.
Details
News Market Reaction – PYPD
The recorded move for PYPD in the trading session of this news was +1.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Efficacy Data of D-PLEX100 in reduction of Surgical Site Infection in Surgical Trauma Injuries will be Presented During a Podium Presentation
PETACH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data and animal study data for D-PLEX100 in surgical trauma injuries will be highlighted in a podium presentation at the 2022 Military Health System Research Symposium (MHSRS) being held on September 12-15, 2022, at the Gaylord Palms Resort and Convention Center, Kissimmee, Florida.
The 2022 Military Health System Research Symposium:
| Title: | D-PLEX100, a doxycycline releasing antimicrobial product for surgical site wounds, reduces surgical site infection rates and drug resistant-bacteria in surgical trauma injuries. |
| Presenter: | Noam Emanuel, PhD, Co-Founder and Chief Scientific Officer, PolyPid. |
| Date: | Monday, September 12, 2022 |
The abstract will be available on www.polypid.com/publications/ following the presentation.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
Media Contact:
Nechama Feuerstein
551-444-0784
Nechama.Feuerstein@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.